

### Case Study: Asthma FDA-Inspected Study

Phase 3 | Respiratory | Pivotal

# **Challenge**

Brick & mortar sites experience significant fatigue in asthma studies, with many sites participating in multiple, similar protocols, leading to:

Burnout Among Site Staff And Investigators: reduced engagement and prioritization of the study.

**Difficulty Enrolling Patients:** the local population were already heavily utilized or unwilling to participate due to study burden.

**Poor Patient Compliance:** due to long travel times, inconvenient visit schedules, and lack of engagement related to the repetitive nature of the studies at these sites

#### Solution

Science 37's Direct-to-Patient Site provided a scalable, patient-centric alternative by removing geographic limitations and accessing untapped patient populations, including:

**Expedited Study Start-Up:** Leveraging our in-house team of research-grade mobile nurses and remote Science 37 investigator oversight.

Rapid, Robust Enrollment: Identifying and enrolling fresh patients across the entire U.S.

**Improved Compliance And Retention:** Conducting study visits in the comfort of the participant's home, minimizing disruptions to daily life, and making participation more convenient.

### Science 37 Results

**Enrolled** 

28%

of Total Study Participants

Science 37 total pts - 712 55 brick & mortar total pts - 1,815 22<sub>x</sub>

Faster Enrollment Compared to Traditional Sites

Science 37 avg. pts/month - 44 Single brick & mortar site avg. pts/month - 2 Top Enrolling Site

**Among 56 Sites** 





**Direct-to-Patient Site** 



## Case Study: Asthma FDA-Inspected Study

Phase 3 | Respiratory | Pivotal







